Immatics stock falls 3.04 percent after cash raise and Q2 miss
Published on 09/24/2026 at 09:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Immatics stock stood at USD 8.60 on Nasdaq on September 23, 2026, down 3.04 percent from the prior close of USD 8.87. The move followed a second quarter in which revenue reached EUR 9.1 million, below the EUR 10.4 million FactSet consensus cited by MarketScreener.
Q2 revenue missed consensus
The revenue gap was EUR 1.3 million, or 12.5 percent below the estimate, making commercial milestone income and collaboration revenue important variables for the clinical-stage biotech. The same Q2 update reported a net loss of EUR 0.46 per share against a FactSet loss estimate of EUR 0.45 per share, according to MarketScreener.
That combination places the emphasis on clinical execution rather than near-term profitability. Immatics is developing T-cell receptor therapies and TCR bispecifics aimed at solid tumors, so trial progress and partnership economics remain central to the valuation.
USD 150 million strengthens funding
Immatics announced on August 25, 2026, that it would sell 12,945,916 ordinary shares at USD 8.69 each and issue pre-funded warrants for 4,315,304 additional shares. The gross proceeds were expected to reach USD 150 million, according to the company's Immatics.
The financing matters because the company is still consuming cash while advancing clinical programs. It also creates dilution, with the announced ordinary shares and warrants adding a defined supply of securities before any future pipeline value is realized.
Stock remains 30.7 percent below high
At USD 8.60, Immatics stock was 30.7 percent below its 52-week high of USD 12.41 and USD 1.70 above its 52-week low of USD 6.90 on September 23, 2026. The market capitalization was USD 1,153,234,200 on the same date, giving the financing and quarterly revenue figures a clear market-value context.
Immatics stock facts
- Company: Immatics N.V.
- Ticker: IMTX
- Trading venue: Nasdaq
- Price as of September 23, 2026: USD 8.60
- Market capitalization: USD 1,153,234,200 as of September 23, 2026
- 52-week range: USD 6.90-12.41 as of September 23, 2026
- Sector / Industry: Healthcare / Biotechnology
